ClinicalTrials.gg
Enrolling by invitationNCT07053527PrEPSchoolUpdated Mar 9, 2026

Welcome to PrEP School Utilizing Peer Educators to Improve Uptake of Preexposure Prophylaxis for HIV at an HBCU

An interventional study of PrEP Awareness and Uptake Educational Program in HIV Prevention Program, sponsored by Morehouse School of Medicine. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 26 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-09.

Sponsored by Morehouse School of Medicine · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
123
Allocation
Not applicable
Ages
18 Years to 26 Years
Sex
All
01

Study summary

This study involves a peer-educator/navigation model targeting gaps in PrEP awareness, uptake, and access in priority populations.

Read the detailed description

The study focuses on increasing awareness and uptake of Pre-Exposure Prophylaxis (PrEP) for HIV prevention among African American college students at a consortium of historically Black colleges and universities in Atlanta, GA.

02

Conditions studied

  • HIV Prevention Program

Keywords

  • Preexposure Prophylaxis
  • PrEP Awareness
  • PrEP Access
  • PrEP Uptake
  • HIV Prevention
  • Peer education
  • HBCU
03

In context

Lead sponsor

Morehouse School of Medicine is the lead sponsor of 22 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 26 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18-26 years old
  • not currently on PrEP
  • English speaking
  • negative
  • 5) Enrolled in the following universities: Spellman College, Morehouse College, Clark Atlanta University, Morehouse school of medicine

Exclusion criteria

Exclusion Criteria:

  • Age \< 18 years old
  • Non-English speaking
  • positive
  • Not currently enrolled any of the four colleges/universities
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
123 participants (estimated)

Study arms

  • Experimental
    Educational Intervention Arm: African American College Students Receiving PrEP Awareness Sessions

    Develop a peer-educator/navigation intervention to help decrease stigma and discrimination and foster knowledge around PrEP use, in the prevention of HIV

    Behavioral: PrEP Awareness and Uptake Educational Program

Interventions

  • BehavioralPrEP Awareness and Uptake Educational Program

    This intervention targets African American college students aged 18-26 using a tailored, community participatory approach. It is delivered by trained peer educators and focuses on increasing PrEP awareness, access, and uptake through interactive, behaviorally focused sessions. Developed with input from focus groups to ensure relevance, the program includes a 6-month follow-up to assess sustained impact, distinguishing it from general PrEP education efforts.

06

What researchers measure

Primary outcomes

  1. Welcome to PrEP School Utilizing Peer Educators to Improve Uptake of Pre-Exposure Prophylaxis for HIV at an HBCU Consortium

    The Primary endpoint will be increased awareness, acceptability and access of PrEP by measuring pre-post surveys after peer-educator/navigator educational intervention.

    Time frame: 12 months

Secondary outcomes

  1. Welcome to PrEP School Utilizing Peer Educators to Improve Uptake of Pre-Exposure Prophylaxis for HIV at an HBCU Consortium

    The secondary endpoint will be measuring clinic data assessing the proportion of college students who initiated PrEP post educational intervention over a 12 months period.

    Time frame: 12 months

07

Study locations

1 site
08

References and documents

Publications

  • Weber S, Lazar L, McCord A, Romero C, Tan J. Online Navigation for Pre-Exposure Prophylaxis via PleasePrEPMe Chat for HIV Prevention: Protocol for a Development and Use Study. JMIR Res Protoc. 2020 Sep 22;9(9):e20187. doi: 10.2196/20187. PubMed 32960183 ↗
  • Truong HM, Pipkin S, O'Keefe KJ, Louie B, Liegler T, McFarland W, Grant RM, Bernstein K, Scheer S. Brief Report: Recent Infection, Sexually Transmitted Infections, and Transmission Clusters Frequently Observed Among Persons Newly Diagnosed With HIV in San Francisco. J Acquir Immune Defic Syndr. 2015 Aug 15;69(5):606-9. doi: 10.1097/QAI.0000000000000681. PubMed 25967271 ↗
  • Pichon LC, Teti M, McGoy S, Murry VM, Juarez PD. Engaging Black men who have sex with men (MSM) in the South in identifying strategies to increase PrEP uptake. BMC Health Serv Res. 2022 Dec 7;22(1):1491. doi: 10.1186/s12913-022-08914-2. PubMed 36476363 ↗
  • Okeke NL, McLaurin T, Gilliam-Phillips R, Wagner DH, Barnwell VJ, Johnson YM, James O, Webb PB, Parker SD, Hill B, McKellar MS, Mitchell JT. Awareness and acceptability of HIV pre-exposure prophylaxis (PrEP) among students at two historically Black universities (HBCU): a cross-sectional survey. BMC Public Health. 2021 May 19;21(1):943. doi: 10.1186/s12889-021-10996-2. PubMed 34006245 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Jul 2026, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 2, 2025
First posted
Jul 8, 2025
StartActual
Sep 23, 2025
Primary completionEst.
Jul 2026
CompletionEst.
Jul 31, 2026
Last update
Mar 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07053527
Lead sponsor
Morehouse School of Medicine
Collaborators
Gilead Sciences
Responsible party
Kara Garretson, MPH (Sr. Epidemiologist and Infection, Prevention & Control Safety Officer for AUCC Student Health Division, Morehouse School of Medicine) — Principal investigator
First posted
Jul 8, 2025
Start date
Sep 23, 2025
Primary completion
Jul 2026 (estimated)
Completion
Jul 31, 2026 (estimated)
Last update
Mar 9, 2026

Study contacts

Kara Garretson
principal investigator · Morehouse School of Medicine

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion